{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.24","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified analysis","nonInferiorityType":"OTHER","pValue":"0.6465","paramType":"Hazard Ratio (HR)","paramValue":"0.94","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit was not reached due to not sufficient number of participants with event.","groupId":"OG000","lowerLimit":"9.23","upperLimit":"NA","value":"17.35"},{"comment":"Upper limit was not reached due to not sufficient number of participants with event.","groupId":"OG001","lowerLimit":"11.99","upperLimit":"NA","value":"28.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Deterioration in Global Health Status/HRQoL is defined as a decrease of at least 10 points on the Global Health Status /HRQoL scale (comprised of 2 items: 29 and 30) of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). The 2 items use 7-point scale (1 = very poor to 7 = Excellent). Scores are averaged, transformed to 0-100 scale; where higher score=better level of functioning or greater degree of symptoms.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"PRO-evaluable populations: participants in the ITT population with baseline PRO assessment and at least one post-baseline PRO assessment in the questionnaire of interest (European Organization for the Research and Treatment of Cancer \\[EORTC\\] Quality-of-life Questionnaire \\[QLQ\\] C30, EORTC QLQ BR-23 or FACT-G)","reportingStatus":"POSTED","timeFrame":"From Day 1 to deterioration, assessed up 64 months","title":"Time to Deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL) in the PRO Evaluable Population","type":"SECONDARY","unitOfMeasure":"Months"}